secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001140361-26-000971
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio reports Q4 Attruby revenue $146M, cash $587.5M; plans two NDAs in H1 2026
--------------------------------------------------------------------------------

- Preliminary unaudited Q4 2025 Attruby net revenue $146M; full year $362.4M; cash, equivalents and securities $587.5M as of Dec 31, 2025.
- 6,629 unique patient prescriptions for Attruby written by 1,632 prescribers as of Dec 31, 2025, reflecting rapid adoption.
- New TTR amyloid depleter antibody program to explore ATTR-CM disease reversal; clinic expected between 2027-2028.
- FDA recommends NDA for BBP-418 (LGMD2I/R9) toward full approval after positive FORTIFY interim; submission planned H1 2026.
- Encumeret NDA for ADH1 planned H1 2026; Phase 3 RECLAIM-HP in chronic hypoparathyroidism to start summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/0001140361-26-000971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126000971/ef20062706_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer